Is Singular Genomics Systems, Inc. overvalued or undervalued?

Jun 25 2025 09:15 AM IST
share
Share Via
As of October 5, 2023, Singular Genomics Systems, Inc. is fairly valued with a price-to-earnings ratio of 25.4, competitive against peers like Illumina and Pacific Biosciences, and has shown slight outperformance against the Sensex.
As of 5 October 2023, Singular Genomics Systems, Inc. moved from overvalued to fairly valued. The company currently exhibits a price-to-earnings ratio of 25.4, a price-to-sales ratio of 5.1, and a price-to-book ratio of 3.2. Compared to its peers, Illumina, Inc. has a price-to-earnings ratio of 39.2, and Pacific Biosciences of California, Inc. stands at 15.8, indicating that Singular Genomics is positioned competitively within its industry.

Given these ratios and the peer comparison, Singular Genomics appears to be fairly valued at this time. The recent stock performance has shown a slight outperformance against the Sensex, which further supports the current valuation assessment.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
What does Singular Genomics Systems, Inc. do?
Jun 22 2025 06:58 PM IST
share
Share Via